Article
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.
Molecular cancer research : MCR - 1 Jan 2019
Leung Grace P, Feng Tianshu, Sigoillot Frederic D, Geyer Felipe C, Shirley Matthew D, Ruddy David A, Rakiec Daniel P, Freeman Alyson K, Engelman Jeffrey A, Jaskelioff Mariela, Stuart Darrin D
Abstract excerpt
The most frequent genetic alterations in melanoma are gain-of-function (GOF) mutations in BRAF, which result in RAF-MEK-ERK signaling pathway addiction. Despite therapeutic success of RAF and MEK inhibitors in treating BRAFV600-mutant tumors, a major challenge is the inevitable emergence of drug resistance, which often involves reactivation of the MAPK pathway. Interestingly, resistant tumors are often sensitive...
Topics
Join the communities discussing this publication.